US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Semaglutide

Reason Subpotent Drug

Boothwyn Pharmacy LLC D-0608-2025
Class II · Moderate risk Ongoing

Semaglutide

Reason Subpotent Drug

Boothwyn Pharmacy LLC D-0606-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets 90 mg

Reason Failed Dissolution Specifications.

Strides Pharma, Inc. NDC 64380-885-04 D-0546-2025
Class II · Moderate risk Completed

Epinephrine Lidocaine HCL

Reason Sub-Potent Drug: Subpotent assay results during stability testing.

Imprimis NJOF, LLC D-0535-2025
Class II · Moderate risk Ongoing

Rizatriptan Benzoate Tablets

Reason CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Ascend Laboratories, LLC NDC 67877-262-18 D-0534-2025
Class II · Moderate risk Ongoing

Rizatriptan Benzoate Tablets

Reason CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Ascend Laboratories, LLC NDC 67877-261-18 D-0533-2025
Class II · Moderate risk Ongoing

Rite Aid Pharmacy

Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield NDC 11822-5156-2 D-0605-2025
Class II · Moderate risk Ongoing

Good Neighbor Pharmacy

Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield NDC 46122-043-78 D-0604-2025
Class II · Moderate risk Ongoing

H-E-B

Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield NDC 37808-809-09 D-0603-2025
Class II · Moderate risk Ongoing

ReliOn

Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield NDC 49035-814-60 D-0602-2025
Class II · Moderate risk Ongoing

CURAD Alcohol Prep Pads

Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield NDC 53329-827-30 D-0601-2025
Class II · Moderate risk Ongoing

Medline Alcohol Prep Pads

Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield NDC 53329-811-30 D-0600-2025
Class II · Moderate risk Ongoing

Timolol Maleate Ophthalmic Solution USP

Reason Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.

FDC Limited NDC 64980-514-05 D-0543-2025
Class II · Moderate risk Terminated

Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg

Reason Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027

Lupin Pharmaceuticals Inc. NDC 68180-755-01 D-0542-2025
Class II · Moderate risk Ongoing

Peripheral Parenteral Nutrition

Reason Lack of Processing Controls; prescriptions were compounded in an ISO-5 area where it was identified that a daily cleaning step was not sufficiently documented.

Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles D-0530-2025
Class II · Moderate risk Ongoing

Budesonide Inhalation Suspension

Reason Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

Cipla USA, Inc. NDC 69097-319-86 D-0541-2025
Class II · Moderate risk Ongoing

Omeprazole Delayed-release Capsules

Reason Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.

Dr. Reddy's Laboratories, Inc. NDC 82009-022-10 D-0525-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Breckenridge Pharmaceutical, Inc. NDC 51991-750-33 D-0511-2025
Class II · Moderate risk Terminated

clomiPRAMINE Hydrochloride Capsules USP 25 mg

Reason Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during retention sample testing at expiry.

Lupin Pharmaceuticals Inc. NDC 68180-492-01 D-0537-2025
Class II · Moderate risk Ongoing

Metoprolol Succinate Extended-Release Tablets

Reason Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.

Granules Pharmaceuticals Inc. NDC 70010-780-01 D-0510-2025
Class II · Moderate risk Ongoing

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Reason Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-456-17 D-0524-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-455-17 D-0523-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-452-17 D-0522-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-451-17 D-0521-2025